AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
sulfur hexafluoride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4039 | 2551-62-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Sulfur hexafluoride. An inert gas used mainly as a test gas in respiratory physiology. Other uses include its injection in vitreoretinal surgery to restore the vitreous chamber and as a tracer in monitoring the dispersion and deposition of air pollutants.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK7,MAPK9,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 51 | |||
| kinase-selectivity-class | ACVR2B,GRK2,PDK4 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 10, 2014 | FDA | BRACCO |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic reaction | 125.16 | 62.49 | 47 | 1258 | 87477 | 90539665 |
| Contrast media reaction | 99.58 | 62.49 | 17 | 1288 | 1234 | 90625908 |
| Flushing | 89.41 | 62.49 | 37 | 1268 | 88454 | 90538688 |
| Unresponsive to stimuli | 86.91 | 62.49 | 29 | 1276 | 38092 | 90589050 |
| Cyanosis | 78.86 | 62.49 | 23 | 1282 | 19432 | 90607710 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic reaction | 275.30 | 76.26 | 93 | 1755 | 42650 | 42576837 |
| Hyperhidrosis | 163.65 | 76.26 | 79 | 1769 | 90433 | 42529054 |
| Feeling hot | 150.31 | 76.26 | 51 | 1797 | 23431 | 42596056 |
| Contrast media reaction | 144.00 | 76.26 | 27 | 1821 | 1089 | 42618398 |
| Flushing | 131.15 | 76.26 | 52 | 1796 | 36976 | 42582511 |
| Anaphylactic shock | 86.55 | 76.26 | 34 | 1814 | 23483 | 42596004 |
| Unresponsive to stimuli | 83.58 | 76.26 | 36 | 1812 | 31367 | 42588120 |
| Hypotension | 82.06 | 76.26 | 76 | 1772 | 257555 | 42361932 |
| Dyspnoea | 77.73 | 76.26 | 95 | 1753 | 442526 | 42176961 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic reaction | 359.01 | 68.65 | 130 | 2928 | 114170 | 110472071 |
| Contrast media reaction | 235.78 | 68.65 | 43 | 3015 | 2355 | 110583886 |
| Hyperhidrosis | 205.72 | 68.65 | 101 | 2957 | 187197 | 110399044 |
| Flushing | 189.37 | 68.65 | 80 | 2978 | 104656 | 110481585 |
| Unresponsive to stimuli | 157.49 | 68.65 | 61 | 2997 | 63729 | 110522512 |
| Feeling hot | 149.44 | 68.65 | 65 | 2993 | 91041 | 110495200 |
| Hypotension | 120.85 | 68.65 | 106 | 2952 | 523743 | 110062498 |
| Dyspnoea | 116.55 | 68.65 | 147 | 2911 | 1106725 | 109479516 |
| Anaphylactic shock | 112.09 | 68.65 | 45 | 3013 | 51501 | 110534740 |
| Cardiac arrest | 104.77 | 68.65 | 66 | 2992 | 196687 | 110389554 |
| Cardio-respiratory arrest | 102.17 | 68.65 | 54 | 3004 | 115782 | 110470459 |
| Pulse absent | 98.33 | 68.65 | 28 | 3030 | 11264 | 110574977 |
| Pulseless electrical activity | 95.72 | 68.65 | 30 | 3028 | 16727 | 110569514 |
| Blood pressure decreased | 91.26 | 68.65 | 50 | 3008 | 115041 | 110471200 |
| Cyanosis | 78.86 | 68.65 | 30 | 3028 | 29711 | 110556530 |
| Erythema | 77.19 | 68.65 | 64 | 2994 | 291383 | 110294858 |
| Nausea | 71.35 | 68.65 | 124 | 2934 | 1235566 | 109350675 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V08DA05 | VARIOUS CONTRAST MEDIA ULTRASOUND CONTRAST MEDIA Ultrasound contrast media |
| FDA MoA | N0000010259 | Ultrasound Contrast Activity |
| FDA EPC | N0000175864 | Contrast Agent for Ultrasound Imaging |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:37337 | ultrasound contrast agent |
| CHEBI has role | CHEBI:62868 | hepatoprotective agent |
| CHEBI has role | CHEBI:76413 | greenhouse gas |
Related Drugs by ATC class:
V08DA Ultrasound contrast media 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 60.7MG/25MG | LUMASON | BRACCO | N203684 | Oct. 15, 2014 | RX | FOR SUSPENSION | INTRAVENOUS | 11723869 | May 15, 2039 | USE IN ADULT AND PEDIATRIC PATIENTS WITH SUBOPTIMAL ECHOCARDIOGRAMS TO OPACIFY THE LEFT VENTRICULAR CHAMBER AND TO IMPROVE THE DELINEATION OF THE LEFT VENTRICULAR ENDOCARDIAL BORDER |
| 60.7MG/25MG | LUMASON | BRACCO | N203684 | Oct. 15, 2014 | RX | FOR SUSPENSION | INTRAVENOUS | 11723869 | May 15, 2039 | USE IN ULTRASONOGRAPHY OF THE URINARY TRACT IN PEDIATRIC PATIENTS FOR THE EVALUATION OF SUSPECTED OR KNOWN VESICOURETERAL REFLUX |
| 60.7MG/25MG | LUMASON | BRACCO | N203684 | Oct. 15, 2014 | RX | FOR SUSPENSION | INTRAVENOUS | 11723869 | May 15, 2039 | USE WITH ULTRASOUND OF THE LIVER IN ADULT AND PEDIATRIC PATIENTS TO CHARACTERIZE FOCAL LIVER LESIONS |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| N0000166210 | NUI |
| D05962 | KEGG_DRUG |
| 4035805 | VANDF |
| C0038779 | UMLSCUI |
| CHEBI:30496 | CHEBI |
| CHEMBL1796998 | ChEMBL_ID |
| D013459 | MESH_DESCRIPTOR_UI |
| DB11104 | DRUGBANK_ID |
| C420843 | MESH_SUPPLEMENTAL_RECORD_UI |
| C523090 | MESH_SUPPLEMENTAL_RECORD_UI |
| WS7LR3I1D6 | UNII |
| 17358 | PUBCHEM_CID |
| 1599276 | RXNORM |
| 22240 | MMSL |
| d05887 | MMSL |
| 010822 | NDDF |
| 259276004 | SNOMEDCT_US |
| 418601008 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| LumaSon | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0270-7097 | INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION | 60.70 mg | INTRAVESICAL | NDA | 24 sections |
| LumaSon | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0270-7097 | INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION | 60.70 mg | INTRAVESICAL | NDA | 24 sections |